Allergic Rhinitis and its Impact on Asthma (ARIA)-EAACI guidelines—2024–2025 revision: part I—guidelines on intranasal treatments
Allergic Rhinitis and its Impact on Asthma (ARIA)-EAACI guidelines—2024–2025 revision: part I—guidelines on intranasal treatments
Background: Allergic rhinitis (AR) impacts quality of life, work and school productivity. Over the last years, an important body of evidence resulting from mHealth data has led to a better understanding of AR. Such advances have motivated an EAACI-endorsed update of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (ARIA 2024–2025). This manuscript presents the ARIA 2024–2025 recommendations for intranasal treatments, one of the mainstays for AR management.
Methods: the ARIA 2024–2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) evidence-to-decision framework. Several sources of evidence were used to inform panel judgments and recommendations, including systematic reviews, evaluation of mHealth and pharmacovigilance data, as well as a survey of experts on costs.
Results: eleven guideline questions concerning intranasal treatments for AR were prioritized, leading to recommendations. Overall, these questions concern the choice between different classes of intranasal medications—most notably, intranasal corticosteroids (INCS), antihistamines (INAH), fixed combinations of INAH+INCS and decongestants—or between different individual medications within each class. Four questions had not been evaluated in previous ARIA guidelines, while for the other three there was a change in the strength or directionality of recommendations. Overall, recommendations point to the suggested use of INAH+INCS over INAH or INCS and INCS over INAH.
Conclusion: this ARIA 2024–2025 article supports patients, their caregivers, and healthcare professionals in choosing an intranasal treatment. However, decisions on AR treatment should consider the clinical variability of the disease, patients' values, and the affordability of medications.
Sousa-Pinto, Bernardo
6f16e57f-0979-47af-83de-fbe725438293
Bousquet, Jean
8065d130-faa7-4c8e-bf40-8d2899980c21
Vieira, Rafael José
66a4766b-336a-4abd-99d2-f0289a0192e5
Roberts, Graham
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Sousa-Pinto, Bernardo
6f16e57f-0979-47af-83de-fbe725438293
Bousquet, Jean
8065d130-faa7-4c8e-bf40-8d2899980c21
Vieira, Rafael José
66a4766b-336a-4abd-99d2-f0289a0192e5
Roberts, Graham
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Roberts, Graham
,
et al.
(2025)
Allergic Rhinitis and its Impact on Asthma (ARIA)-EAACI guidelines—2024–2025 revision: part I—guidelines on intranasal treatments.
Allergy.
(doi:10.1111/all.70131).
Abstract
Background: Allergic rhinitis (AR) impacts quality of life, work and school productivity. Over the last years, an important body of evidence resulting from mHealth data has led to a better understanding of AR. Such advances have motivated an EAACI-endorsed update of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (ARIA 2024–2025). This manuscript presents the ARIA 2024–2025 recommendations for intranasal treatments, one of the mainstays for AR management.
Methods: the ARIA 2024–2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) evidence-to-decision framework. Several sources of evidence were used to inform panel judgments and recommendations, including systematic reviews, evaluation of mHealth and pharmacovigilance data, as well as a survey of experts on costs.
Results: eleven guideline questions concerning intranasal treatments for AR were prioritized, leading to recommendations. Overall, these questions concern the choice between different classes of intranasal medications—most notably, intranasal corticosteroids (INCS), antihistamines (INAH), fixed combinations of INAH+INCS and decongestants—or between different individual medications within each class. Four questions had not been evaluated in previous ARIA guidelines, while for the other three there was a change in the strength or directionality of recommendations. Overall, recommendations point to the suggested use of INAH+INCS over INAH or INCS and INCS over INAH.
Conclusion: this ARIA 2024–2025 article supports patients, their caregivers, and healthcare professionals in choosing an intranasal treatment. However, decisions on AR treatment should consider the clinical variability of the disease, patients' values, and the affordability of medications.
Text
Allergy - 2025 - Sousa‐Pinto - Allergic Rhinitis and Its Impact on Asthma ARIA ‐EAACI Guidelines 2024 2025 Revision Part
- Version of Record
More information
Accepted/In Press date: 21 September 2025
e-pub ahead of print date: 1 December 2025
Identifiers
Local EPrints ID: 508370
URI: http://eprints.soton.ac.uk/id/eprint/508370
ISSN: 0105-4538
PURE UUID: 99767e46-be9b-4a19-9907-afc6eefac410
Catalogue record
Date deposited: 20 Jan 2026 17:41
Last modified: 21 Jan 2026 02:39
Export record
Altmetrics
Contributors
Author:
Bernardo Sousa-Pinto
Author:
Jean Bousquet
Author:
Rafael José Vieira
Corporate Author: et al.
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics